Versameb AG: Versameb Names Dr Alexandre LeBeaut as Chair of the Board of Directors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Mural Oncology Launches To Advance Pipeline Of Novel Engineered Cytokine Immunotherapies menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program
Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including